Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

169.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results
--News Direct-- 
Via News Direct
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Natera, Inc. (NTRA) Investors
From Kirby McInerney LLP
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Analyzing Natera's Unusual Options Activity
On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o... 
Via Benzinga
What Does Natera's Debt Look Like?
Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
Expert Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observe... 
Via Benzinga
Analyst Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observed... 
Via Benzinga
Natera Announces Expansion Into Early Cancer Detection and Screening
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Natera Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
7 Stocks to Buy in November in Light of Their October Dip
October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick. 
Via InvestorPlace
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc... 
Via Benzinga
Natera Raises FY21 Sales Outlook After Mixed Q3 earnings
Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product... 
Via Benzinga
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
NTRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
CEO And President Of Natera Trades $2.4M In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Notable Natera Insider Trades $3M In Company Stock
Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
CEO And President Of Natera Trades $3.41 Million In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Return on Capital Employed Overview: Natera
After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a... 
Via Benzinga
Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook
Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings
Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue... 
Via Benzinga
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space. 
Via The Motley Fool
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.